Cidara Therapeutics stock price target raised to $173 by Citizens

Cidara Therapeutics (NASDAQ:CDTX) has received significant analyst upgrades, including Citizens raising its price target to $173, following a substantial BARDA contract potentially worth $339 million for its influenza preventative, CD388. This funding, alongside positive FDA feedback that expanded the Phase 3 trial's eligible patient population, has significantly de-risked the program and expanded its market potential, bolstering investor confidence in the company's outlook.

Analysis

Cidara Therapeutics (CDTX) is experiencing significant positive momentum driven by two key developments for its influenza preventative, CD388. Firstly, the company secured a contract with the Biomedical Advanced Research and Development Authority (BARDA) with a total potential value of $339 million, including an initial $58 million over two years. This substantial non-dilutive funding de-risks the program's advancement by supporting manufacturing and clinical trials. This catalyst directly prompted Citizens to increase its probability of success estimate for CD388 from 65% to 75%, leading to a price target hike to $173. Secondly, positive feedback from the FDA has enabled a significant expansion of the ongoing Phase 3 ANCHOR trial, effectively doubling the potential eligible patient base in the U.S. from 50 million to over 100 million. This has materially increased the drug's total addressable market. The market's positive reception is reflected in the stock's 820% return over the past year and a strong consensus 'Buy' rating from analysts, with firms like Guggenheim also raising targets to $167 in response to the favorable regulatory and funding environment.

Key Decisions for Investors

• Consider the recent BARDA contract and expanded Phase 3 trial as significant de-risking events for CD388, supporting the bullish analyst consensus and justifying a positive stance on the stock.
• Given the stock's 820% year-over-year return and current trading price above some analyst targets, investors should be mindful that significant optimism may already be priced in, warranting a careful assessment of the valuation.
• Monitor progress and interim updates from the 6,000-participant Phase 3 ANCHOR trial, as clinical data will be the next major catalyst determining whether CD388 can achieve its expanded market potential.